Salud financiera de hoja de balance de Jazz Pharmaceuticals
Salud financiera controles de criterios 1/6
Jazz Pharmaceuticals tiene un patrimonio de accionistas total de $3.7B y una deuda total de $5.7B, lo que sitúa su ratio deuda-patrimonio en 153%. Sus activos y pasivos totales son $11.4B y $7.7B respectivamente. El BAIT de Jazz Pharmaceuticals es de $810.7M, por lo que su ratio de cobertura de intereses es de 2.8. Tiene efectivo e inversiones a corto plazo que ascienden a $1.6B.
Información clave
153.0%
Ratio deuda-patrimonio
US$5.72b
Deuda
| Ratio de cobertura de intereses | 2.8x |
| Efectivo | US$1.63b |
| Patrimonio | US$3.74b |
| Total pasivo | US$7.66b |
| Activos totales | US$11.39b |
Actualizaciones recientes sobre salud financiera
Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?
Feb 18
Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly
Oct 31Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?
Jul 12We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt
Apr 12Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly
Aug 10Jazz Pharmaceuticals (NASDAQ:JAZZ) Takes On Some Risk With Its Use Of Debt
May 12Recent updates
Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off
Apr 15Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price
Apr 02Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?
Feb 18Updated View On Jazz Pharmaceuticals' 2025 Goals
Jan 29Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking
Dec 26Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly
Oct 31Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?
Jul 12We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt
Apr 12Jazz Pharmaceuticals: Monopoly In The Narcolepsy Drug Market
Aug 24Jazz begins phase 3 trial of cannabis drug Epidiolex for rare epilepsy
Aug 18Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly
Aug 10Jazz Pharmaceuticals: Strong Launch Of Xywav In Idiopathic Hypersomnia
Jun 08Jazz Pharmaceuticals (NASDAQ:JAZZ) Takes On Some Risk With Its Use Of Debt
May 12Jazz Pharmaceuticals: Imminent Danger With A Worrying History
Feb 04Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($3.4B) de JAZZ superan a sus pasivos a corto plazo ($1.5B).
Pasivo a largo plazo: Los activos a corto plazo ($3.4B) de JAZZ no cubren sus pasivos a largo plazo ($6.1B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: La relación deuda neta-capital de JAZZ (109.3%) se considera alta.
Reducción de la deuda: El ratio deuda-patrimonio de JAZZ ha crecido de 57.9% a 153% en los últimos 5 años.
Cobertura de la deuda: La deuda de JAZZ no está bien cubierta por el flujo de caja operativo (19.1%).
Cobertura de intereses: Los pagos de intereses de la deuda de JAZZ no están bien cubiertos por el BAIT (2.8x cobertura).